Non‐clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance®) to neonatal and juvenile rats

@article{Bussi2018NonclinicalAO,
  title={Non‐clinical assessment of safety and gadolinium deposition after cumulative administration of gadobenate dimeglumine (MultiHance{\textregistered}) to neonatal and juvenile rats},
  author={Simona Bussi and Laure Penard and Roberta Bonaf{\'e} and Catherine Botteron and Roberto Celeste and Alessandra Coppo and Roberta Queliti and Miles A Kirchin and Fabio Tedoldi and Federico Maisano},
  journal={Regulatory Toxicology and Pharmacology},
  year={2018},
  volume={92},
  pages={268–277}
}
View on Wolters Kluwer
ncbi.nlm.nih.gov
12 Citations
Highly Influential Citations
1
Background Citations
2

Figures and Tables from this paper

12 Citations

Citation Type

Citation Type

Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure
TLDR
The findings suggest that gadolinium does not lead to histopathological or ultrastructural changes in the brain and demonstrate in detail the kinetics of a human equivalent dose over time in a pre-clinical model.
Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration
TLDR
The purpose of this review is to highlight what is currently known in the literature regarding the pharmacokinetics of gadolinium in humans and animals, and any toxicity associated with GBCA use.
Comprehensive phenotyping revealed transient startle response reduction and histopathological gadolinium localization to perineuronal nets after gadodiamide administration in rats
TLDR
The behavioral finding together with Gd distribution and speciation support a substance class difference for Gd presence in the brain after GBCA application and a transient and reversible decrease of the startle reflex after gadodiamide application.
Detection of gadolinium deposition in cortical bone with ultrashort echo time T1 mapping: an ex vivo study in a rabbit model
TLDR
The results suggest that UTE T1 mapping has the potential to provide a non-invasive assessment of gadolinium deposition in cortical bone following GBCA administration.
The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green
TLDR
Gadoxetate disodium inhibited the ATP-binding cassette sub-family C member 2 transporter and tended to inhibit hepatic ICG uptake, which is likely to inhibit liver parenchymal uptake.
Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants
TLDR
Gadobenate dimeglumine is safe and effective for pediatric MR imaging and exact matching of each specific MR imaging–determined diagnosis with the on-site final diagnosis were achieved in significantly more patients by each reader following evaluation of combined pre- and postcontrast images relative to precont contrast images alone.
Gadolinium Deposition in Brain: Current Scientific Evidence and Future Perspectives
TLDR
This review summarizes the current evidence on gadolinium deposition in the human and animal bodies, evaluates the effects of different types of GBCAs on the gadolinia deposition, introduces the possible entrance or clearance mechanism of the Gadolinium and potential side effects that may be related to the gadoliniium deposition on human or animals, and puts forward some suggestions for further research.
MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis.
Dose‐Lowering in Contrast‐Enhanced MRI of the Central Nervous System: A Retrospective, Parallel‐Group Comparison Using Gadobenate Dimeglumine
TLDR
Higher relaxivity gadobenate may be suited to reduced dose protocols, and concerns over gadolinium (Gd) retention encourage the use of lower Gd doses, but these doses may compromise imaging performance.
Does Gadoterate Meglumine Cause Gadolinium Retention in the Brain of Children? A Case–Control Study
TLDR
A significant T1 SI increase reflecting gadolinium retention in the brain was detected for children with at least three gadoterate meglumine administrations in this series, and the number of administrations correlated well with the increased SI.
...
1
2
...

References

SHOWING 1-10 OF 63 REFERENCES
Non-clinical safety assessment of gadoterate meglumine (Dotarem(®)) in neonatal and juvenile rats.
Comparison of Gadolinium Concentrations within Multiple Rat Organs after Intravenous Administration of Linear versus Macrocyclic Gadolinium Chelates.
TLDR
Tissue deposition of gadolinium was two- to fourfold higher following administration of the linear agents gadodiamide and gadobenate dimeglumine compared with the macrocyclic agents gadobutrol and gadoteridol, suggesting that organ tissue deposition is reduced but not eliminated following Administration of macrocyclIC GBCA chelates in lieu of linear chelate.
Safety profiles of gadolinium chelates in juvenile rats differ according to the risk of dissociation.
Clearance of Gadolinium from the Brain with No Pathologic Effect after Repeated Administration of Gadodiamide in Healthy Rats: An Analytical and Histologic Study.
TLDR
Low levels of gadolinium are present in the brain after repeat dosing with gadodiamide, which is partially cleared over 20 weeks with no detectable neurotoxicity.
Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents
TLDR
A correlation between the complex stability of G BCAs and the amount of residual Gd in the skin up to a year after application of GBCAs is observed.
Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance), a new magnetic resonance imaging contrast medium.
TLDR
Based on the wide margins of safety demonstrated in different species, particularly in primates, gadobenate dimeglumine can be considered as safe in the range of clinical doses recommended for magnetic resonance imaging.
Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation.
  • N. Fretellier, M. Salhi, C. Corot
  • Biology, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2015
Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats.
TLDR
The retention of Gd in the skin with gadodiamide was associated with an increase in dermal cellularity, and Gd encrustation of collagen fibers and deposition inside the fibroblasts and other cells, and was higher than gadoteric acid.
Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
TLDR
Gadodiamide injection has been shown to have a remarkably low acute lethal toxicity, superior to that of gadopentetate dimeglumine injection, and had fewer effects on cardiovascular and hemodynamic function after rapid intravenous injection in anesthetized dogs and, in vitro at high concentrations, on erythrocyte fragility and arterial wall tension.
A Review of Preclinical Safety Data for Magnevist (Gadopentetate Dimeglumine) in the Context of Nephrogenic Systemic Fibrosis
TLDR
Preclinical safety data from in vivo studies in healthy rats and dogs conducted with Magnevist during the drug development process in the mid-80s were reassessed to analyze whether the acquired knowledge on NSF would lead to a revised interpretation of the original preclinical data.
...
1
2
3
4
5
...